JP2010504343A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504343A5
JP2010504343A5 JP2009529307A JP2009529307A JP2010504343A5 JP 2010504343 A5 JP2010504343 A5 JP 2010504343A5 JP 2009529307 A JP2009529307 A JP 2009529307A JP 2009529307 A JP2009529307 A JP 2009529307A JP 2010504343 A5 JP2010504343 A5 JP 2010504343A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methoxymethyl
dimethylamino
der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009529307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504343A (ja
JP5184536B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/078352 external-priority patent/WO2008036541A1/en
Publication of JP2010504343A publication Critical patent/JP2010504343A/ja
Publication of JP2010504343A5 publication Critical patent/JP2010504343A5/ja
Application granted granted Critical
Publication of JP5184536B2 publication Critical patent/JP5184536B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009529307A 2006-09-20 2007-09-13 チオフェンピラゾロピリミジン化合物 Expired - Fee Related JP5184536B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82627306P 2006-09-20 2006-09-20
US60/826,273 2006-09-20
PCT/US2007/078352 WO2008036541A1 (en) 2006-09-20 2007-09-13 Thiophene pyrazolopyrimidine compounds

Publications (3)

Publication Number Publication Date
JP2010504343A JP2010504343A (ja) 2010-02-12
JP2010504343A5 true JP2010504343A5 (enExample) 2010-11-04
JP5184536B2 JP5184536B2 (ja) 2013-04-17

Family

ID=38988344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529307A Expired - Fee Related JP5184536B2 (ja) 2006-09-20 2007-09-13 チオフェンピラゾロピリミジン化合物

Country Status (12)

Country Link
US (1) US8110580B2 (enExample)
EP (1) EP2076515B1 (enExample)
JP (1) JP5184536B2 (enExample)
KR (1) KR101088196B1 (enExample)
CN (1) CN101516886B (enExample)
AU (1) AU2007297481B2 (enExample)
BR (1) BRPI0717070A2 (enExample)
CA (1) CA2662000C (enExample)
EA (1) EA016056B1 (enExample)
ES (1) ES2428543T3 (enExample)
MX (1) MX2009003098A (enExample)
WO (1) WO2008036541A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
WO2010090716A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
TW201307309A (zh) 2010-10-13 2013-02-16 Millennium Pharm Inc 雜芳基化合物及其用途
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RS65839B1 (sr) 2014-01-21 2024-09-30 Neurocrine Biosciences Inc Crf1 receptor antagonisti za tretman kongenitalne adrenalne hiperplazije
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
EP3238676B1 (en) 2016-04-29 2019-01-02 The Procter and Gamble Company Absorbent core with profiled distribution of absorbent material
WO2019036503A1 (en) 2017-08-14 2019-02-21 Spruce Biosciences, Inc. CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS
JP7285222B2 (ja) * 2017-08-14 2023-06-01 スプルース バイオサイエンシズ インコーポレイテッド 副腎皮質刺激ホルモン放出因子受容体拮抗薬
EP4643950A3 (en) 2018-04-27 2026-01-14 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
US20220023266A1 (en) 2018-12-07 2022-01-27 Neurocrine Biosciences, Inc. Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
JP7623365B2 (ja) 2019-09-27 2025-01-28 ニューロクライン バイオサイエンシーズ,インコーポレイテッド Crf受容体アンタゴニストおよび使用方法
TW202134241A (zh) * 2019-12-04 2021-09-16 美商紐羅克里生物科學有限公司 Crf受體拮抗劑及使用方法
KR20240023691A (ko) 2020-08-12 2024-02-22 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
AU713673B2 (en) * 1996-02-07 1999-12-09 Neurocrine Biosciences Inc. Pyrazolopyrimidines as crf receptor antagonists
HU229024B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された6,5―ヘテロ―二環式誘導体
ES2277855T3 (es) * 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
MY143499A (en) * 2003-12-22 2011-05-31 Sb Pharmco Inc Crf receptor antagonist and methods relating thereto
EP1869049B1 (en) * 2005-03-21 2009-03-04 Eli Lilly And Company Imidazopyridazine compounds

Similar Documents

Publication Publication Date Title
JP2010504343A5 (enExample)
JP2012502037A5 (enExample)
JP2007145875A5 (enExample)
JP2013542247A5 (enExample)
JP2010526814A5 (enExample)
JP2009502743A5 (enExample)
JP2010521514A5 (enExample)
JP2009545527A5 (enExample)
JP2010077141A5 (enExample)
JP2013510123A5 (enExample)
JP2007302689A5 (enExample)
JP2010536889A5 (enExample)
JP2014515013A5 (enExample)
JP2010501478A5 (enExample)
JP2014500861A5 (enExample)
JP2008539268A5 (enExample)
JP2010502730A5 (enExample)
JP2009507896A5 (enExample)
JP2011518833A5 (enExample)
JP2013509429A5 (enExample)
JP2011528658A5 (enExample)
JP2006524660A5 (enExample)
JP2009537554A5 (enExample)
JP2008539267A5 (enExample)
JP2012512863A5 (enExample)